Twin SUBLIVAC® Grasses Clinical Efficay Study - niet van toepassing

HAL Allergenen Lab0 个研究点目标入组 25 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•Subjects with allergic rhinoconjunctivitis with or without mild asthma (FEV1 >= 70%) for at least 2 years. Their allergic symptoms should be related to grass pollen
•Use of anti-allergy symptomatic medication in the last pollen season (or, in case of a low pollen season, in one of the two previous years)
•A positive skin prick test (>3 mm) for grasses and specific serum IgE-test
•(>1 U/ml) for grass pollen (Lolium perenne, Phleum pratense and Poa pratensis).
•Age 12 years or older.
•Subjects (and their parents if required) shall give a written informed consent

•A positive SPT for perennial allergens of house dust mite
•Symptoms related to concomitant sensitisation to perennial allergens of pets
•Chronic asthma or emphysema, particularly with a FEV1 < 70 % of predicted value or use of inhalation corticosteroids outside grass and tree pollen season for more than two episodes and/or longer than fourteen days
•Use of symptomatic medication for more than three episodes and/or longer than three days outside the tree- or grasspollen season
•Serious immuno-pathological diseases or malignancies (including auto-immune diseases, tuberculosis, HIV)
•Inflammation and infection of the target organ
•Severe atopic dermatitis requiring systemic immuno-suppressive medication
•Allergen specific immuno-therapy treatment within the last 5 years for a period longer than three months

发起方

HAL Allergenen Lab